Welcome to our dedicated page for Biohaven SEC filings (Ticker: BHVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. (BHVN) is offering 23,333,334 common shares at $7.50 per share in a primary offering. The deal totals $175,000,005 before fees, with underwriting discounts of $0.45 per share. The company estimates net proceeds of approximately $164.0 million and plans to use the funds for general corporate purposes.
The underwriters have a 30‑day option to buy up to 3,500,000 additional shares. Common shares outstanding are expected to be 129,136,989 immediately after the offering, or 132,636,989 if the option is fully exercised. Certain insiders, including the CEO, have indicated interest in purchasing about $60,000,000 of shares, with $5,000,000 indicated by the CEO; these indications are not binding. A 30‑day lock‑up applies to the company and to directors and officers. BHVN trades on the NYSE; the last reported sale was $8.52 on November 11, 2025.
Biohaven Ltd. is conducting a $150,000,000 primary offering of common shares pursuant to a prospectus supplement. The deal includes a 30‑day option for underwriters to purchase additional shares after pricing.
The company expects to use net proceeds for general corporate purposes. Insider interest is indicated at approximately $60,000,000 in aggregate, including about $5,000,000 from the CEO, subject to allocation by underwriters. Biohaven’s common shares trade on the NYSE under “BHVN”; the last reported price was $7.79 on November 10, 2025.
As context, 105,803,655 common shares were outstanding as of September 30, 2025; this is a baseline figure, not the amount being offered. The company has a 30‑day lock‑up, and directors and officers are subject to similar lock‑ups, with customary exceptions described under “Underwriting.”
Biohaven Ltd. (BHVN) reported a larger quarterly loss and added new debt to fund its pipeline. For Q3 2025, net loss was $173.4 million compared with $160.3 million a year ago. Operating expenses were $169.4 million, with research and development at $141.2 million and general and administrative at $28.2 million. Net investment income was $3.4 million.
Liquidity shifted toward cash: cash and cash equivalents were $184.8 million and marketable securities were $75.4 million as of September 30, 2025. Year‑to‑date, operating cash outflows totaled $478.8 million, partly offset by $250.0 million of proceeds from senior secured notes issued in April 2025. Notes payable measured at fair value were $268.3 million at quarter‑end. A derivative liability related to a prior agreement declined to $22.0 million.
Shareholders’ equity moved to a deficit of $17.2 million, from $423.4 million at December 31, 2024, reflecting continued losses and fair value adjustments. The company stated it expects existing cash, cash equivalents, marketable securities, and equity purchase commitments to fund operations for at least one year after issuance of these financial statements. Common shares outstanding were 105,803,655 as of September 30, 2025.
Biohaven Ltd. (BHVN) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The company reported this event on November 10, 2025.
The information was provided under Item 2.02 and includes Exhibit 99.1 titled “Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments.” As noted under General Instruction B.2., the Item 2.02 information and Exhibit 99.1 are furnished, not filed.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership in Biohaven Ltd (BHVN). The filing states ownership of 2,875,190 shares, representing 2.71% of the company’s common stock as of 09/30/2025.
The filing details show sole voting power: 0 shares and shared voting power: 535,665 shares. Vanguard reports sole dispositive power: 2,228,799 shares and shared dispositive power: 646,391 shares. Vanguard is identified as an investment adviser (IA) and certifies the securities were acquired and are held in the ordinary course of business, not to change or influence control. Vanguard notes its clients have rights to dividends or sale proceeds, and no other person’s interest exceeds 5%.
Biohaven Ltd. (BHVN) reported that the FDA's Division of Neurology 1 extended the PDUFA review for the troriluzole NDA by three months in May 2025 to allow a full review of recent submissions. At that time the Division had planned an advisory committee meeting to discuss the application.
On August 21, 2025 the Division informed the company that an advisory committee meeting is no longer needed for regulatory decision making. The FDA's decision on the NDA is expected during the fourth quarter of 2025. The report and Exhibit 99.1 are being furnished and are not "filed" for Section 18 purposes.
Biohaven Ltd. filed a prospectus supplement covering the resale by a selling shareholder of 3,588,688 common shares that were issued as share consideration under an amended acquisition agreement.
The amendment to the Knopp Biosciences purchase arrangement replaces a scaled high single digit to low teens royalty with a flat mid-single digit royalty on BHV-7000 and related pipeline programs. It also removes up to $562.5 million in commercial sales-based milestones and reduces developmental and regulatory milestones from up to $575 million to up to $210 million tied to BHV-7000 approvals across multiple regions, plus up to $60 million tied to U.S. approval of other Kv7 programs. Biohaven can choose to pay these contingent milestones in cash or in its common shares.
Biohaven Ltd. (BHVN) prospectus supplement describes registered resale of 3,588,688 common shares issued to a selling shareholder under the May 1, 2024 Amendment to the Membership Interest Purchase Agreement (the "Knopp Amendment"). The Knopp Amendment replaces a scaled high-single-digit/low-teens royalty with a flat mid-single-digit royalty for BHV-7000 and pipeline programs, removes up to $562.5 million in commercial sales-based milestones and reduces development/regulatory milestones from up to $575 million to up to $210 million for BHV-7000 (with $25 million already paid) plus up to $60 million for other Kv7 programs in the U.S.; Biohaven may pay these contingent milestones in cash or common shares.
The filing summarizes corporate charter terms under BVI law, authorized share limits (200,000,000 common; 10,000,000 preferred), and reports 105,790,997 common shares issued and outstanding as of August 14, 2025. It also discloses governance provisions that may allow the Board to issue preferred shares without shareholder approval and other anti-takeover features.
Janus Henderson Group plc reports beneficial ownership of 5,053,528 shares of Biohaven Ltd. common stock, representing approximately 4.9% of the class. The position is disclosed as shared voting and shared dispositive power held through Janus Henderson subsidiaries that act as registered investment advisers to managed portfolios.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Biohaven, and it includes a power of attorney delegating authority to named compliance officers to execute required ownership filings.
Biohaven Ltd. reported a continued operating loss and a material financing transaction that altered its balance sheet. Total assets were $550.4 million versus $615.1 million at year-end, with $165.8 million in cash and cash equivalents and $239.2 million in marketable securities. The company recorded a net loss of $198.1 million for the quarter and $419.8 million for the six months, with basic and diluted loss per share of $1.94 and $4.11, respectively.
Biohaven completed a $250.0 million secured notes financing under a Note Purchase Agreement and elected fair-value accounting for those notes, which increased non-current notes payable to $257.1 million and raised total liabilities to $415.8 million. Research and development expense declined versus the prior-year periods, reducing operating expense and operating loss, but operating cash use remained substantial at $333.1 million for the six months. The company also reported significant contingent milestone and commercial payment obligations under license and acquisition agreements totaling up to $3.185 billion, which are not recognized as liabilities because the triggering events were not considered probable.